Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Wed, Nov 27, 2024
[Archive]
Volume 15, Issue 2 (8-2001)
Med J Islam Repub Iran 2001 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
NASSERI P, GHAVAMZADEH A, KEYHANI ELAHI M, SHARIFIAN R, NATEGHI J, ALIMOGHADAM K, et al . EFFECT OF LONG- AND SHORT-TERM MINICONSOLIDATION ON SURVIVAL OF PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA. Med J Islam Repub Iran 2001; 15 (2) :61-66
URL: http://mjiri.iums.ac.ir/article-1-804-en.html
URL: http://mjiri.iums.ac.ir/article-1-804-en.html
P NASSERI 
, A GHAVAMZADEH , M KEYHANI ELAHI , RA SHARIFIAN , J NATEGHI , K ALIMOGHADAM , MR MORTAZAVIZADEH , M ABASI , MR ESHRAGHIAN
, A GHAVAMZADEH , M KEYHANI ELAHI , RA SHARIFIAN , J NATEGHI , K ALIMOGHADAM , MR MORTAZAVIZADEH , M ABASI , MR ESHRAGHIAN
From the Department of Hematology-Oncology, Tehran University of Medical Sciences, Tehran, I.R. Iran.
Abstract: (5006 Views)
A retrospective study was done on 130 AML patients treated in Shariati and
Imam Hospitals in Tehran from 1991 to 1997 to investigate the value of three
post-remission methods of treatment.
All patients who were in complete remission (CR) (Group I) had been treated
with ARA-C (300 mg/m2/day continuous infusion for 5 days) and Daunorubicine
(45 mg/m2/day for 3 days) as induction and early consolidation therapy. Forty
patients were treated by additional similar chemotherapy as second consolidation
and no further treatment was offered. Fifty patients (Group II) were treated by
ARA-C (120 mg/m2 subcutaneously for 5 days), Etoposide (120 mg/m2 on day
one), and Mitoxantrone (12 mg/m2 on day one) on each successive month as
short-term miniconsolidation. Forty patients (Group III) were treated similarly to
Group II until relapse for up to two years as long-term miniconsolidation.
There was no difference in the three groups regarding mean age and other
prognostic factors. Treatment related mortality and morbidity were also similar.
Median duration of disease-free survival (DFS) was 36 (3.5-68 with 95% CI), 17
(12.5-21.5) and 19 (14.7-23.3) months respectively in these three groups. In a 14-
month median observation there was no difference in DFS and overall survival
(OS) among the three groups (p=0.7).
We concluded that short- or long-term miniconsolidation chemotherapy compared
to standard treatment does not improve DFS and OS in AML patients.
Type of Study: Original Research |
Subject:
Oncology
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
